Making Gains Against Triple-Negative Breast Cancer
Executive Summary
Researchers reported on new approaches to the knotty problem of triple-negative breast cancer, using genomics to identify ways of targeting the intractable disease with drugs already in the industry pipeline, at the San Antonio Breast Cancer Symposium Dec. 4-8.
You may also be interested in...
Generex Likes Chances For Partnering AE37 Breast Cancer Vaccine
The vaccine trains specialized immune cells to act against a HER2 peptide. Created using Antigen Express’ Ii-Key Hybrid platform, Generex says AE37 has none of the restrictions that will limit the market potential of other HER2 peptide vaccines in development.
HDAC Inhibitor Mysteries Remain As Candidates Advance
With more than a dozen candidates in the clinic and a range of indications expanding outside oncology, the histone deacetylase inhibitor class could be poised to make major inroads. But much remains to be learned about the activity, and companies are scrambling to find biomarkers.
Sanofi-Aventis Could Refocus Development For PARP Inhibitor Iniparib
The French pharma is standing by the first-in-class drug, which failed in a Phase III trial in triple-negative breast cancer, saying it conferred a benefit in heavily pretreated patients.